Evidence map›Paper›PMID 37861717›Full record

ArticleHuman genetics2023

KAT6A mutations in Arboleda-Tham syndrome drive epigenetic regulation of posterior HOXC cluster.

Meghna Singh, Sarah J Spendlove, Angela Wei, Leroy M Bondhus, Aileen A Nava, Francisca N de L Vitorino, Seth Amano, Jacob Lee, Gesenia Echeverria, Dianne Gomez and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Human genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

  • Update of
    2023
5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Meghna SinghDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Sarah J SpendloveDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Angela WeiDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Leroy M BondhusDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Aileen A NavaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Francisca N de L VitorinoDepartment of Biochemistry and Molecular Biophysics, Washington University in St. Louis, St. Louis, MO, USA.
Seth AmanoDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Jacob LeeDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Gesenia EcheverriaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Dianne GomezDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Benjamin A GarciaDepartment of Biochemistry and Molecular Biophysics, Washington University in St. Louis, St. Louis, MO, USA.
Valerie A ArboledaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA. vaa2001@g.ucla.edu.
University of California, Los Angeles · USWashington University in St. Louis · USUCLA Health · US

Funding

Shared Resources Core 2: Quantitative Proteomics CoreP01CA196539 · NCI · ROCKEFELLER UNIVERSITY · PI MUIR, TOM · 2015 to 2024
$17.6M
Quantitative mass spectrometry for comprehending epigenetic mechanisms in a new underlying neurological developmental disorderR01HD106051 · NICHD · WASHINGTON UNIVERSITY · PI Benjamin A Garcia · 2022 to 2026
$2.6M
A Mass Spectrometry Approach to the Genetic and Epigenetic Mechanisms Controlling Neuronal IdentityR01NS111997 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI DAHMANE, NADIA, GARCIA, BENJAMIN A · 2020 to 2024
$2.6M
Unraveling correlations between Mendelian and common disease using functional genomicsDP5OD024579 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARBOLEDA, VALERIE A · 2017 to 2021
$1.9M
Identifying sources of variable penetrance and expressivity in monogenic diseases at population scaleF31HG013462 · NHGRI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WEI, ANGELA N · 2024 to 2025
$86k
Elucidating the pathogenic mechanisms by which KAT6A mutations alter human in vitro neurodevelopmentF31NS141668 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Aileen Anai Nava · 2025 to 2026
$84k
NCI NIH HHS P01 CA196539NHGRI NIH HHS F31 HG013462NICHD NIH HHS R01 HD106051NIH HHS DP5 OD024579NIH HHS DP5OD024579NIH HHS F31HG013462NIH HHS NS111997NINDS NIH HHS F31 NS141668NINDS NIH HHS R01 NS111997
6 · The paper itself

Abstract

Arboleda-Tham Syndrome (ARTHS) is a rare genetic disorder caused by heterozygous, de novo mutations in Lysine(K) acetyltransferase 6A (KAT6A). ARTHS is clinically heterogeneous and characterized by several common features, including intellectual disability, developmental and speech delay, and hypotonia, and affects multiple organ systems. KAT6A is the enzymatic core of a histone-acetylation protein complex; however, the direct histone targets and gene regulatory effects remain unknown. In this study, we use ARTHS patient (n = 8) and control (n = 14) dermal fibroblasts and perform comprehensive profiling of the epigenome and transcriptome caused by KAT6A mutations. We identified differential chromatin accessibility within the promoter or gene body of 23% (14/60) of genes that were differentially expressed between ARTHS and controls. Within fibroblasts, we show a distinct set of genes from the posterior HOXC gene cluster (HOXC10, HOXC11, HOXC-AS3, HOXC-AS2, and HOTAIR) that are overexpressed in ARTHS and are transcription factors critical for early development body segment patterning. The genomic loci harboring HOXC genes are epigenetically regulated with increased chromatin accessibility, high levels of H3K23ac, and increased gene-body DNA methylation compared to controls, all of which are consistent with transcriptomic overexpression. Finally, we used unbiased proteomic mass spectrometry and identified two new histone post-translational modifications (PTMs) that are disrupted in ARTHS: H2A and H3K56 acetylation. Our multi-omics assays have identified novel histone and gene regulatory roles of KAT6A in a large group of ARTHS patients harboring diverse pathogenic mutations. This work provides insight into the role of KAT6A on the epigenomic regulation in somatic cell types.

Indexed as

Epigenesis, GeneticHistonesChromatinHistone AcetyltransferasesHomeodomain ProteinsHumansMutationProteomicsTranscription FactorsChromatinHistone AcetyltransferasesHistonesHomeodomain ProteinsHOXC10 protein, humanHOXC11 protein, humanKAT6A protein, humanTranscription Factors

Identifiers

PMID37861717
PMCPMC10676314
OpenAlexW4387798596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.